JP2020519625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519625A5 JP2020519625A5 JP2019562001A JP2019562001A JP2020519625A5 JP 2020519625 A5 JP2020519625 A5 JP 2020519625A5 JP 2019562001 A JP2019562001 A JP 2019562001A JP 2019562001 A JP2019562001 A JP 2019562001A JP 2020519625 A5 JP2020519625 A5 JP 2020519625A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- groups
- compound according
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 125000001624 naphthyl group Chemical group 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003277 amino group Chemical group 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 14
- -1 (-O)- Chemical class 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 12
- 125000006850 spacer group Chemical group 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 230000002209 hydrophobic effect Effects 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 229930195733 hydrocarbon Natural products 0.000 claims 6
- 150000002430 hydrocarbons Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000003132 pyranosyl group Chemical group 0.000 claims 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 150000001720 carbohydrates Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 239000004215 Carbon black (E152) Substances 0.000 claims 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 4
- 125000000623 heterocyclic group Chemical class 0.000 claims 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 102000000802 Galectin 3 Human genes 0.000 claims 3
- 108010001517 Galectin 3 Proteins 0.000 claims 3
- 125000003843 furanosyl group Chemical group 0.000 claims 3
- 150000008195 galaktosides Chemical class 0.000 claims 3
- 239000001257 hydrogen Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052711 selenium Inorganic materials 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000001177 diphosphate Substances 0.000 claims 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 2
- 235000011180 diphosphates Nutrition 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- PMMURAAUARKVCB-DUVQVXGLSA-N 2-deoxy-D-galactopyranose Chemical class OC[C@H]1OC(O)C[C@@H](O)[C@H]1O PMMURAAUARKVCB-DUVQVXGLSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010001498 Galectin 1 Proteins 0.000 claims 1
- 102100021736 Galectin-1 Human genes 0.000 claims 1
- 102000044445 Galectin-8 Human genes 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101710121810 Galectin-9 Proteins 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- XXMPGRFKPAPNJH-UHFFFAOYSA-N N1N=NC=C1.FC1=CC=CC=C1 Chemical compound N1N=NC=C1.FC1=CC=CC=C1 XXMPGRFKPAPNJH-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 235000008935 nutritious Nutrition 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505544P | 2017-05-12 | 2017-05-12 | |
| US62/505,544 | 2017-05-12 | ||
| PCT/US2018/032349 WO2018209255A1 (en) | 2017-05-12 | 2018-05-11 | Compounds for the prevention and treatment of diseases and the use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519625A JP2020519625A (ja) | 2020-07-02 |
| JP2020519625A5 true JP2020519625A5 (enExample) | 2021-07-26 |
| JP7204676B2 JP7204676B2 (ja) | 2023-01-16 |
Family
ID=64105444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562001A Active JP7204676B2 (ja) | 2017-05-12 | 2018-05-11 | 疾患の予防および治療用の化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11576924B2 (enExample) |
| EP (1) | EP3621973A4 (enExample) |
| JP (1) | JP7204676B2 (enExample) |
| KR (1) | KR102626669B1 (enExample) |
| CN (1) | CN110869378B (enExample) |
| AU (1) | AU2018265571B2 (enExample) |
| BR (1) | BR112019023722A2 (enExample) |
| CA (1) | CA3062648A1 (enExample) |
| IL (1) | IL270469B2 (enExample) |
| MX (1) | MX392945B (enExample) |
| WO (1) | WO2018209255A1 (enExample) |
| ZA (1) | ZA201908165B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117883A1 (en) * | 2018-12-06 | 2020-06-11 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| JP7547345B2 (ja) * | 2018-12-27 | 2024-09-09 | グリコミメティクス， インコーポレイテッド | ガレクチン－３阻害性ｃ－グリコシド |
| EP3947407B1 (en) | 2019-03-26 | 2024-06-12 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| CN115244045A (zh) * | 2019-12-24 | 2022-10-25 | 糖模拟物有限公司 | 抑制半乳凝素-3的c-糖苷酮、醚和醇 |
| US12275720B2 (en) | 2020-05-05 | 2025-04-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2021231243A1 (en) | 2020-05-11 | 2021-11-18 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CN115768768A (zh) | 2020-05-28 | 2023-03-07 | 百时美施贵宝公司 | 半乳凝素-3抑制剂 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
| WO2022184755A1 (en) | 2021-03-03 | 2022-09-09 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3812681A1 (de) * | 1988-04-16 | 1989-11-02 | Bayer Ag | Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| GB9626450D0 (en) * | 1996-12-20 | 1997-02-05 | Oxford Glycosciences Uk Ltd | Therapeutic compounds |
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| GB0501008D0 (en) | 2005-01-18 | 2005-02-23 | Amura Therapeutics Ltd | Method of producing conjugate vaccines |
| US9427449B2 (en) | 2005-08-26 | 2016-08-30 | Econugenics, Inc. | Binding of galectin-3 by low molecular weight pectin |
| AU2007319806A1 (en) | 2006-11-15 | 2008-05-22 | The Brigham And Women's Hospital, Inc. | Therapeutic uses of TIM-3 modulators |
| US8697862B2 (en) | 2008-05-16 | 2014-04-15 | Galecto Biotech Ab | Synthesis of galactoside inhibitors |
| ES2652488T3 (es) * | 2009-04-28 | 2018-02-02 | Galecto Biotech Ab | Nuevos inhibidores de galactósidos de galectinas |
| EA201270316A1 (ru) | 2009-08-25 | 2012-09-28 | БиДжи МЕДИСИН, ИНК. | Галектин-3 и сердечная ресинхронизирующая терапия |
| WO2011095772A2 (en) | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| CA2794066C (en) | 2012-10-31 | 2017-02-28 | Neil Henderson | Galactoside inhibitor of galectins |
| US9243021B2 (en) | 2012-10-31 | 2016-01-26 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| CA2848711C (en) | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| CN104245717B (zh) | 2011-12-28 | 2017-10-24 | 卡莱克汀医疗有限公司 | 用于治疗人类疾病的新型糖类药物的组合物 |
| EP2620443A1 (en) | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (enExample) * | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| EP3125908A4 (en) | 2014-03-10 | 2017-11-15 | La Jolla Pharmaceutical Company | Compositions and methods for treating kidney disorders |
| US20170095496A1 (en) | 2014-04-08 | 2017-04-06 | Galecto Biotech Ab | Galactoside inhibitors for new uses |
| JP6735680B2 (ja) | 2014-07-09 | 2020-08-05 | ガレクト バイオテック エービー | ガレクチンの新規ハイブリッドガラクトシド阻害剤 |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US10799522B2 (en) | 2015-07-27 | 2020-10-13 | Wayne State University | Compositions and methods relating to galectin detection |
| CA3000924A1 (en) | 2015-11-09 | 2017-05-18 | Galecto Biotech Ab | Novel galactoside inhibitors of galectins |
| US20190367552A1 (en) * | 2016-03-04 | 2019-12-05 | Galectin Sciences, Llc | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
-
2018
- 2018-05-11 KR KR1020197036413A patent/KR102626669B1/ko active Active
- 2018-05-11 JP JP2019562001A patent/JP7204676B2/ja active Active
- 2018-05-11 EP EP18797833.3A patent/EP3621973A4/en active Pending
- 2018-05-11 WO PCT/US2018/032349 patent/WO2018209255A1/en not_active Ceased
- 2018-05-11 BR BR112019023722-4A patent/BR112019023722A2/pt not_active Application Discontinuation
- 2018-05-11 CA CA3062648A patent/CA3062648A1/en active Pending
- 2018-05-11 CN CN201880045752.6A patent/CN110869378B/zh active Active
- 2018-05-11 US US16/611,609 patent/US11576924B2/en active Active
- 2018-05-11 MX MX2019013537A patent/MX392945B/es unknown
- 2018-05-11 AU AU2018265571A patent/AU2018265571B2/en active Active
-
2019
- 2019-11-06 IL IL270469A patent/IL270469B2/en unknown
- 2019-12-09 ZA ZA2019/08165A patent/ZA201908165B/en unknown
-
2022
- 2022-06-08 US US17/835,363 patent/US20230132265A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529988A5 (enExample) | ||
| JP2022121594A5 (enExample) | ||
| JP5087052B2 (ja) | 改良された治療剤 | |
| BR112019023722A2 (pt) | Compostos para a prevenção e tratamento de doenças e o uso dos mesmos | |
| JP2019507194A5 (enExample) | ||
| JP2009541225A5 (enExample) | ||
| JP2016501838A5 (enExample) | ||
| EP0805815A1 (en) | Bismuth compounds | |
| JP2013504590A5 (enExample) | ||
| CA2658313C (en) | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives | |
| CN101583362B (zh) | 当以乳清酸盐衍生物给药时降低甲氨蝶呤副作用和毒性的组合物和方法 | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| US4239905A (en) | 1-β-D-Arabinofuranosylcytosine-5'-oleyl phosphate and salts thereof | |
| US6958324B2 (en) | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | |
| JP4435861B2 (ja) | 新規なスルホン酸化糖誘導体およびその医薬としての使用 | |
| CN115252603A (zh) | indisulam在制备治疗膀胱癌的药物中的应用 | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| PT88568B (pt) | Processo para a preparacao de derivados de sacaridos | |
| JP2023518299A5 (enExample) | ||
| CN107827908B (zh) | 一种雷帕霉素三氮唑衍生物及其制备方法和用途 | |
| Tsybulskaya et al. | Phospholipid derivatives of cladribine and fludarabine: Synthesis and biological properties | |
| US20150183780A1 (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
| JP2010500971A5 (enExample) | ||
| EP1383505A2 (en) | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease | |
| JP2015533128A5 (enExample) |